IgM-enriched human introvenous immunoglobulin strongly inhibits complement-dependent porcine cell cytotoxicity mediated by human xenoreactive antibodies.
Treatment with intravenous immunoglobulin preparations consisting of human IgG (IVIgG) prevents hyperacute rejection of pig xenografts transplanted into primates by inhibition of the classical complement pathway. Recent studies indicate that IVIg preparations mainly consisting of human IgM (IVIgM) have a stronger capacity than IVIgG to inhibit the complement system. IVIg preparations also contain xenoreactive antibodies (XAb) binding to pig cells. In the present study, we compared IVIgG and IVIgM for their capacity to inhibit xenogeneic complement activation, with special reference to the roles of IgG and IgM XAb present in these preparations. Xenogeneic complement activation was studied by exposure of pig cells (PK15) to human serum. For some experiments, IVIgG and IVIgM were depleted from XAb by immune absorption. Exposure of PK15 cells to human serum induced surface deposition of C4 and C3 and cytotoxicity, which could be inhibited in a dose-dependent fashion by both IVIgM and IVIgG. The efficacy of IVIgM was more than 10 times higher than that of IVIgG. IgG XAb were detected IVIgG and IVIgM whereas IgM XAb were only present in IVIgM. Depletion of XAb from the IVIg preparations did not modify the protective properties of IVIgG against cytotoxicity induced by human serum, whereas the IVIgM-mediated protection against xenogeneic cytotoxicity was only slightly improved. IgM-enriched IVIg is a potent inhibitor of xenogeneic complement activation and complement-dependent cytotoxicity of human serum to pig cells, irrespective of the presence of cytotoxic xenoreactive IgM antibodies in this preparation. Therefore, IVIgM has a promising therapeutic significance for the treatment of (hyper)acute xenograft rejection.
Roos
Anja
A
Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands. a.roos@lumc.nl
Rieben
Robert
R
Faber-Krol
Maria C
MC
Daha
Mohamed R
MR
D000818:Animals; D000910:Antibodies, Heterophile / Q000276:immunology*; D015478:Antigens, Heterophile / Q000276:immunology* / Q000378:metabolism; D003167:Complement Activation; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic; D004187:Disaccharides / Q000276:immunology; D006084:Graft Rejection; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D007075:Immunoglobulin M / Q000276:immunology*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000276:immunology; D044967:Serum / Q000276:immunology; D013552:Swine
D000910:Antibodies, Heterophile; D015478:Antigens, Heterophile; D004187:Disaccharides; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016756:Immunoglobulins, Intravenous; C055075:galactosyl-(1-3)galactose